| Autor: |
Stinson JA; Massachusetts Institute of Technology, Cambridge, MA, United States., Sheen A; Massachusetts Institute of Technology, Cambridge, MA, United States., Lax BM; Massachusetts Institute of Technology, Cambridge, MA, United States., Yang GN; Massachusetts Institute of Technology, Cambridge, MA, United States., Duhamel L; Massachusetts Institute of Technology, Cambridge, MA, United States., Santollani L; Massachusetts Institute of Technology, Cambridge, MA, United States., Fink E; Massachusetts Institute of Technology, Cambridge, MA, United States., Palmeri J; Massachusetts Institute of Technology, Cambridge, MA, United States., Wittrup KD; Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, United States. |
| Abstrakt: |
While heightened intratumoral levels of reactive oxygen species (ROS) are typically associated with a suppressive tumor microenvironment, under certain conditions ROS contribute to tumor elimination. Treatment approaches, including some chemotherapy and radiation protocols, increase cancer cell ROS levels that influence their mechanism of cell death and subsequent recognition by the immune system. Furthermore, activated myeloid cells rapidly generate ROS upon encounter with pathogens or infected cells to eliminate disease, and recently, this effector function has been noted in cancer contexts as well. Collectively, ROS-induced cancer cell death may help initiate adaptive anti-tumor immune responses that could synergize with current approved immunotherapies, for improved control of solid tumors. In this work, we explore the use of glucose oxidase, an enzyme which produces hydrogen peroxide, a type of ROS, to therapeutically mimic the endogenous oxidative burst from myeloid cells to promote antigen generation within the tumor microenvironment. We engineer the enzyme to target pan-tumor expressed integrins both as a tumor-agnostic therapeutic approach, but also as a strategy to prolong local enzyme activity following intratumoral administration. We found the targeted enzyme potently induced cancer cell death and enhanced cross-presentation by dendritic cells in vitro, and further combined with interferon alpha for long-term tumor control in murine MC38 tumors in vivo. Optimizing the single-dose administration of this enzyme overcomes limitations with immunogenicity noted for other pro-oxidant enzyme approaches. Overall, our results suggest ROS-induced cell death can be harnessed for tumor control, and highlight the potential use of designed enzyme therapies alongside immunotherapy against cancer. |
